Abstract
This month's issue of the Journal features a study by McMakin et al. 1 McMakin D.L. Olino T.M. Porta G. et al. Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor-treatment resistant depression. J Am Acad Child Adolesc Psychiatry. 2012; 51: 404-411 Abstract Full Text Full Text PDF PubMed Scopus (251) Google Scholar that examines the impact of anhedonia on the rates of recovery for adolescents with treatment-resistant depression. 1 McMakin D.L. Olino T.M. Porta G. et al. Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor-treatment resistant depression. J Am Acad Child Adolesc Psychiatry. 2012; 51: 404-411 Abstract Full Text Full Text PDF PubMed Scopus (251) Google Scholar Based on data collected in the Treatment of Selective Serotonin Reuptake Inhibitor-Resistant Depression in Adolescents (TORDIA) study, 2 Brent D. Emslie G. Clarke G. et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA. 2008; 299: 901-913 Crossref PubMed Scopus (458) Google Scholar , 3 Asarnow J.R. Emslie G. Clarke G. et al. Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response. J Am Acad Child Adolesc Psychiatry. 2009; 48: 330-339 Abstract Full Text Full Text PDF PubMed Google Scholar the article establishes that anhedonia uniquely predicts a more protracted course of depression and emphasizes the importance of anhedonia for diagnosis and prognosis. Thanks to landmark studies such as the Treatment for Adolescents with Depression Study (TADS) 4 Kennard B.D. Silva S.G. Tonev S. et al. Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): acute and long-term outcomes. J Am Acad Child Adolesc Psychiatry. 2009; 48: 186-195 Abstract Full Text Full Text PDF PubMed Scopus (126) Google Scholar and TORDIA, cognitive behavioral therapy and pharmacotherapy in concert are widely accepted as the evidence-based treatment of choice for depression in adolescents. However, anhedonia, a key symptom in major depression, presages a poorer outcome even in the face of well-delivered, empirically based treatments. Anhedonia Predicts Poorer Recovery Among Youth With Selective Serotonin Reuptake Inhibitor Treatment–Resistant DepressionJournal of the American Academy of Child & Adolescent PsychiatryVol. 51Issue 4PreviewTo identify symptom dimensions of depression that predict recovery among selective serotonin reuptake inhibitor (SSRI) treatment–resistant adolescents undergoing second-step treatment. Full-Text PDF
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the American Academy of Child & Adolescent Psychiatry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
